Newfoundland and Labrador Prescription Drug Program
Dear Provider:
Please note that the following DINs are Open Benefit to All Plans under NLPDP and Special Authorization for Cystics effective the April 1, 2008:
| DIN | Product Name | MFG |
| 2295377 | Apo-Glimepiride Tablet | APX |
| 2274248 | Co Glimepiride Tablet | COB |
| 2273756 | Novo-Glimepiride Tablet | NOP |
| 2273101 | ratio-Glimepiride Tablet | RPH |
| 2269589 | Sandoz Glimepiride Tablet | SDZ |
| 2295385 | Apo-Glimepiride Tablet | APX |
| 2274256 | Co Glimepiride Tablet | COB |
| 2273764 | Novo-Glimepiride Tablet | NOP |
| 2273128 | ratio-Glimepiride Tablet | RPH |
| 2269597 | Sandoz Glimepiride Tablet | SDZ |
| 2295393 | Apo-Glimepiride Tablet | APX |
| 2274272 | Co Glimepiride Tablet | COB |
| 2273772 | Novo-Glimepiride Tablet | NOP |
| 2273136 | ratio-Glimepiride Tablet | RPH |
| 2269619 | Sandoz Glimepiride Tablet | SDZ |